High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity

Kidney International

Volumn 64, Issue 2, 2003, Pages 728-736

  Deicher, Robert ^a   Ziai, Farzad ^b   Cohen, Gerald ^b   Müllner, Marcus ^b   Hörl, Walter H ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Chronic kidney failure; Iron; Neutrophils; Randomized controlled trial

Indexed keywords

CD11B ANTIGEN; COMPLEMENT COMPONENT C3; CYTOKINE; FC RECEPTOR; FERRIC HYDROXIDE SUCROSE; LACTOFERRIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; NEUTROPHIL; PERITONEAL DIALYSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY BURST; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037781677     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00125.x     Document Type: Article

References (47)

1. WORKING PARTY FOR EUROPEAN BEST PRACTICE GUIDELINES FOR THE MANAGEMENT OF ANAEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE: European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14(Suppl 5):1-50, 1999
2. VYCHYTIL A, HAAG-WEBER M: Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int(Suppl 69):S71-S78, 1999
3. MACDOUGALL IC: Intravenous administration of iron in epoetin-treated haemodialysis patients - Which drugs, which regimen? Nephrol Dial Transplant 15:1743-1745, 2000
4. ZANEN AL, ADRIAANSEN HJ, VAN BOMMEL EFH, et al: 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 11:820-824, 1996
5. ROOB JM, KHOSCHSORUR G, TIRAN A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
6. MCCORD JM: Iron, free radicals, and oxidative injury. Semin Hematol 35:5-12, 1998
7. FELDMAN HI, SANTANNA J, Guo W, et al: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13:734-744, 2002
8. HOEN B, PAUL-DAUPHIN A, HESTIN D, KESSLER M: EPIBACIDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9:869-876, 1998
9. BOELAERT JR, DANEELS RF, SCHURGERS M. et al: Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 5:130-134, 1990
10. GREEN NS: Yersinia infections in patients with homzygous beta-thalassemia associated with iron overload and its treatment. Pediatr Hematol Oncol 9:247-254, 1992
11. HOEN B, KESSLER M, HESTIN D, MAYEUX D: Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 10:377-381, 1995
12. VAN ASBECK BS, MARX JJ, STRUYVENBERG A, VERHOEF J: Functional defects in phagocytic cells from patients with iron overload. J Infect 8:232-240, 1984
13. WATERLOT Y, CANTINIEAUX B, HARIGA-MULLER C, et al: Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. Br Med J (Clin Res Ed) 291:501-504, 1985
14. VEYS N, VANHOLDER R, RINOOIR S: Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients. Am J Kidney Dis 19:358-363, 1992
15. PATRUTA SI, EDLINGER R, SUNDER-PLASSMANN G, HÖRL WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Neprhrol 9:655-663, 1998
16. + flux. Nature 416:291-297, 2002
17. BORTNER CA, MILLER RD, ARNOLD RR: Bactericidal effect of lactoferrin on Legionella pneumophila. Infect Immun 51:373-377, 1986
18. ELLISON RT, 3RD, GIEHL TJ, LAFORCE FM: Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56:2774-2781, 1988
19. BELAAOUAJ A, KIM KS, SHAPIRO SD: Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. Science 289:1185-1188, 2000
20. ELLISON RT, 3RD, GIEHL TH: Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 88:1080-1091, 1991
21. CHANDLER G, HARCHOWAL J, MACDOUGALL IC: Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 38:988-991, 2001
22. LACSON E, DIAZ-Buxo JA: The treatment of anemia in peritoneal dialysis patients. Clin Nephrol 56:415-427, 2001
23. 2 production in adherent human neutrophils. J Immunol 152:290-300, 1994
24. MACHIN D, CAMPBELL M, FAYERS P, PINOL A: Sample Size Tables for Clinical Studies, 2nd edition, London, Blackwell Science, 1997
25. MOIOLA F: Phagocytosis, F-actin polymerization and cell volume of bovine neonatal neutrophils: a comparative study with adult cattle [dissertation]. University of Bern, 1992
26. HAMPTON MB, WINTERBOURN CC: Methods for quantifying phagocytosis and bacterial killing by human neutrophils. J Immunol Methods 232:15-22, 1999
27. GOLDNER M, FARKAS-HIMSLEY H, KORMENDY A, SKINNER M: Bacterial phagocytosis monitored by fluorescence and extracellular quenching: Ingestion and intracellular killing. Lab Med 14:291-294, 1983
28. NATHAN CF: Neutrophil activation on biological surfaces: Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 80:1550-1560, 1987
29. ALTMAN DG: Practical Statistics for Medical Research, London, Chapman & Hall, 1992, pp 431-433
30. DEICHER R, EXNER M, COHEN G, et al: Neutrophil β(2)-microglobulin and lactoferrin content in renal failure patients. Am J Kidney Dis 35:1117-1126, 2000
31. HEGNHOJ J, SCHAFFALITZKY DE MUCKADELL OB: An enzyme linked immunosorbent assay for measurements of lactoferrin in duodenal aspirates and other biological fluids. Scand J Clin Lab Invest 45:489-495, 1985
32. ARMITAGE P, BERRY G: Multiple measurements, in Statistical Methods in Medical Research, Blackwell Scientific Publications, 3rd edition, 1994, pp 312-385,
33. GLEASON JR: Within subjects (repeated measures) ANOVA, including between subjects factors. Stata Tech Bull Reprints 8:236-243, 1999
34. FORSBERG M, LÖFGREN R, ZHENG L, STENDHAL O: Tumour necrosis factor-alpha potentiates CR3-induced respiratory burst by activating p38 MAP kinase in human neutrophils. Immunology 103:465-472, 2001
35. HIRABAYASHI Y, KOBAYASHI T, NISHIKAWA A, et al: Oxidative metabolism and phagocytosis of polymorphonuclear leukocytes in patients with chronic renal failure. Nephron 49:305-312, 1988
36. VANHOLDER R, RINGOIR S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 3:1541-1554, 1993
37. VANHOLDER R, DE SMET R, JACOBS V, et al: Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 9:1271-1278, 1994
38. ALEXIEWICZ JM, SMOGORZEWSKI M, KLIN M, et al: Effect of treatment of hemodialysis patients with nifedipine on metabolism and function of polymorphonuclear leukocytes. Am J Kidney Dis 25:440-444, 1995
39. AHMED A, KROL E, SMOGORZEWSKI M, MASSRY SG: Effect of amlodipine therapy on the monoclonal antibody 3G8-induced calcium signal in polymorphonuclear leukocytes of hemodialysis patients. Am J Nephrol 19:505-508, 1999
40. HOEPELMAN IM, JAARSMA EY, VERHOEF J, MARX JJ: Polynuclear iron complexes impair the function of polymophonuclear granulocytes. Br J Haematol 68:385-389, 1988
41. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
42. BESARAB A, AMIN N, AHSAN M, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538, 2000
43. BURNS DL, MASCIOLI CA, BISTRIAN BR: Effect of iron-supplemented total parenteral nutrition in patients with iron deficiency anemia. Nutrition 12:411-415, 1996
44. STEPHAN F, YANG K, TANKOVIC J, et al: Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 30:315-322, 2002
45. HEKKER TAM, GROENEVELD ABJ, SIMOONS-SMIT AM, et al: Role of bacterial virulence factors and host factors in the outcome of Escherichia coli bacteraemia. Eur J Clin Microbiol Infect Dis 19:312-316, 2000
46. LIM PS, WEI YH, Yu YL, KOH B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14:2680-2687, 1999
47. HERRERA J, NAVA M, ROMERO F, RODRIGUEZ-ITURBE B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37:750-757, 2001